Business
Trading Update
MedPal AI plc reported a strong December 2025 trading update, processing 33,433 prescription orders for approximately £325,000 turnover, a 16% month-on-month increase, driven by its NHS Distance Selling Pharmacy contract and private weight loss service. The company is well-positioned to benefit from the FDA's approval of Novo Nordisk's oral GLP-1 medication for weight loss, which is expected to significantly expand the market by removing barriers associated with injectable treatments. MedPal.clinic, utilizing Google's Vertex AI, is poised to capitalize on this expanded opportunity through its AI-powered triage and prescription fulfillment capabilities. Disclaimer*
About this update from Medpal Ai Plc
[{"type":"text","content":"\n\n5 January 2026\nMedPal AI plc\n(\"MedPal AI\" or the \"Company\")\nTrading Update - Pharmacy Operations\n \nFDA Approves First Oral GLP-1 for Weight Loss\n \n \nMedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence (\"AI\") company focused on health and wellness management, is pleased to provide a trading update on its pharmacy operations for December 2025 and that Novo Nordisk's Wegovy pill has now been approved by the FDA.\n \nTrading Update - Pharmacy Operations\n \nDuring December 2025, MedPal Limited processed 33,433 prescription orders through its automated pharmacy operations, generating turnover of approximately £325,000 at an average item value of £9.72. This represents month-on-month growth of approximately 16% compared with November 2025's 28,789 prescriptions, a particularly strong performance given the shortened trading month due to the Christmas period.\n \nThe continued scaling of prescription volumes reflects both the successful integration of the NHS Distance Selling Pharmacy (\"DSP\") contract and growing uptake of the Company's private weight loss service launched via MedPal.clinic.\n \nFDA Approves First Oral GLP-1 for Weight Loss\n \nOn 22 December 2025, the US Food and Drug Administration (\"FDA\") approved Novo Nordisk's Wegovy pill (oral semaglutide 25mg), making it the first oral GLP-1 medication approved for weight management. This landmark approval represents a paradigm shift in obesity treatment, offering patients a once-daily pill alternative to weekly injections.\n \nClinical trials demonstrated that the oral formulation achieved weight loss of up to 16.6% in adherent patients over 64 weeks, a result that is comparable to the injectable form. The Directors believe this development will significantly expand the addressable market for GLP-1 therapies, as many patients who are reluctant to use injectable medications may now consider treatment. The oral format removes barriers such as needle aversion and refrigeration requirements, potentially bringing millions of new patients into the weight management market.\n \nMedPal.clinic, powered by Google's Vertex AI platform, is well positioned to capitalise on this expanded market opportunity through its established AI-powered triage and prescription fulfilment capabilities.\n \...